-
Sign In
- Sony Biotechnology
- Sony Biotechnology
Presented by LabRoots
Although immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some patients do not respond, or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology.
Join this free webinar to learn how researchers are integrating cell sorting, RNA sequencing, ex-vivo phenotype profiling, and patient-derived xenografts to study the mechanisms of PD-L1 resistance in cancer.
With this webinar, you will:
Researchers who want to integrate a multi-omics approach in their clinical studies on immune checkpoint inhibitor resistance will gain valuable insights. In addition, the webinar will benefit those who want to learn about new technologies for isolating and profiling tumor cells.